With a likely FDA approval for its blockbuster bone drug denosumab looming next month, Amgen researchers took to the stage at a Berlin conference to outline the therapy's benefits for breast cancer patients. The drug delayed skeletal deterioration in women with advanced breast cancer better than Novartis' Zometa, the data indicates. And the drug also delayed the worsening of bone pain in the comparison study. Amgen is already building a sales force for the drug, which is widely expected to gain official FDA approval. Report